News-ScinoPharm Taiwan, Ltd.

19

Mar 2026

Performance

ScinoPharm Taiwan Actively Responds to Government Pharmaceutical Policy, Strengthening Local Supply Chain Resilience

ScinoPharm Taiwan (TWSE: 1789) held its investor conference today to present its 2025 operating results and business progress. Consolidated revenue for the year reached NT$3.163 billion, with net profit after tax of NT$137 million and earnings per share (EPS) of NT$0.17. Through ongoing product mix optimization and cost control, the Company maintained a stable gross margin.

21

Jan 2026

Performance

ScinoPharm Taiwan Announces Approval of Bortezomib Injection for Multiple Myeloma Treatment in Taiwan, Strengthening Domestic Pharmaceutical Supply Chain Resilience

ScinoPharm Taiwan announced that it has successfully obtained marketing approval from the Taiwan Food and Drug Administration (TFDA) for Bortezomib, a treatment for Multiple Myeloma. Following the U.S. FDA approval secured in 2023, the newly granted Taiwan approval marks another significant milestone for the company. This achievement not only highlights ScinoPharm Taiwan’s decades-long expertise in oncology drug development, but also demonstrates its concrete response to the government’s policy to strengthen pharmaceutical supply chain resilience. ScinoPharm Taiwan is currently actively pursuing National Health Insurance reimbursement approval, with the goal of benefiting more patients in Taiwan and firmly anchoring internationally recognized critical manufacturing technologies and high-quality medicines within the local healthcare system.

05

Jan 2026

Performance

ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis

ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) approval for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS), making it the only pharmaceutical company in Taiwan to achieve this historic milestone. This achievement underscores ScinoPharm’s leadership in complex generics and highlights Taiwan’s growing recognition as a trusted contributor to the global pharmaceutical industry.

04

Nov 2025

ScinoPharm Taiwan 15th in 2025 CSR “Small Giants”

Honored as a 2025 CSR “Small Giants” top 15 company by CommonWealth Magazine.

16

Oct 2025

ScinoPharm Taiwan Hosts Healing Art Forum in Partnership with Formosa Cancer Foundation

ScinoPharm Taiwan recently held its 16th annual ScinoPharm Art Forum, a long-standing public art and cultural lecture series dedicated to enriching lives through art and dialogue.

19

Aug 2025

Performance

ScinoPharm Taiwan Continues Strategic Expansion in Formulation and CDMO Businesses

ScinoPharm Taiwan (Stock Code: 1789) held an online investor conference today to report its financial results for the first half of 2025. The company recorded consolidated revenue of US$45.2 million, equivalent to NT$1.434 billion, and a net profit after tax of NT$80 million.